Press release
Key Influencer in the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market 2025: Rising Incidence Of Multiple Myeloma Driver
B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size
Over the recent years, the market size for B-cell maturation antigen (BCMA) targeted therapies has seen a massive growth. The market is expected to expand from $12.17 billion in 2024 to $15.21 billion in 2025 with a compound annual growth rate (CAGR) of 25.0%. The significant growth during the historic period is due to an increased focus on hematologic malignancies, enhanced investments in cancer research, rising popularity of personalized medicine, wider acceptance of CAR-T cell therapies, and increasing healthcare spending.
The market size for therapies targeting B-cell maturation antigen (BCMA) is forecasted to experience a significant surge in the coming years. It is set to increase to $36.66 billion in 2029, showcasing a compound annual growth rate (CAGR) of 24.6%. This substantial growth in the projected timeframe can be credited to a rising emphasis on cancer study, a shift towards targeting particular molecular markers, and the growing incidence of cancer. Other contributing factors include a rise in biotech investments and an intensified use of gene and cell therapies. Noteworthy trends predicted for the period include innovative breakthroughs such as CRISPR technology, enhancement in gene-editing technologies, progression in the next-generation car-t cell therapies, advancements in targeted antibody-drug conjugates, and the creation of ready-to-use treatments.
What Factors Are Propelling the Expansion of the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?
The b-cell maturation antigen (BCMA) targeted therapies market is expected to be spurred by the increasing prevalence of multiple myeloma. This cancer primarily affects the body's plasma cells, which play a significant role in the immune system as they are responsible for antibody production. Factors such as the aging global population, enhanced diagnostic tools, and variations in healthcare accessibility are contributing to the higher incidence of multiple myeloma. BCMA targeted therapies are essential in treating this condition as they specifically target and eradicate harmful plasma cells that express BCMA, providing a promising route towards more effective and targeted treatment. For example, data from the American Cancer Society, a professional organization based in the US, shows that in August 2024, an estimated 35,780 new cases of multiple myeloma were identified in the country, with 19,520 cases in men and 16,260 in women. The organization also anticipates around 12,540 deaths, including 7,020 in men and 5,520 in women. Consequently, the escalating incidence of multiple myeloma is fueling growth in the b-cell maturation antigen (BCMA) targeted therapies market.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20718&type=smp
Which Businesses Are at the Forefront of B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Development?
Major companies operating in the B-cell maturation antigen (BCMA) targeted therapies market are Bristol Myers Squibb Company, Novartis, GlaxoSmithKline (GSK), Takeda Pharmaceutical Company Limited, Amgen Inc, Regeneron Pharmaceuticals, Beigene, Arcellx Inc, Poseida Therapeutics, Legend Biotech Corporation, Cartesian Therapeutics, Juno Therapeutics, Sutro Biopharma Inc, CARsgen Therapeutics, Precision BioSciences, Eureka Therapeutics Inc, Cellectis, Teneobio Inc., Janssen Pharmaceuticals Companies, Allogene Therapeutics, Affimed, Bluebird Bio Inc.
How Is the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Evolving?
Leading businesses in the B-cell maturation antigen (BCMA) targeted therapies industry are putting their efforts into the creation of innovative treatments like CAR-T cell therapy to boost the efficacy and accuracy of cancer cell targeting. CAR-T cell therapy is an immunotherapy form which involves altering a patient's T cells to express chimeric antigen receptors (CARs) for the purpose of targeting and eliminating cancer cells. For instance, in April 2024, Johnson & Johnson, an American pharmaceutical company, was granted approval by the U.S. Food and Drug Administration (FDA) for CARVYKTI. CARVYKTI (ciltacabtagene autoleucel) is a BCMA-targeted, genetically modified autologous T-cell immunotherapy used for treating adult patients dealing with relapsed or refractory multiple myeloma, that have undergone at least one prior line of therapy and are resistant to lenalidomide.
How Is the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Segmented?
The B-cell maturation antigen (BCMA) targeted therapies market covered in this report is segmented -
1) By Product Type: Antibody Drug Conjugates, Chimeric Antigen Receptor T (CAR-T)-Cell Therapy, Bispecific Antibodies
2) By Indication Type: Acute Lymphoblastic Leukemia, Multiple Myeloma
3) By End User: Hospitals, Specialty Clinics, Home Care Settings
Subsegments:
1) By Antibody Drug Conjugates: BCMA-Targeted ADCs (Antibody-Drug Conjugates), Linker-Payload Technology-Based BCMA ADCs
2) By Chimeric Antigen Receptor T (CAR-T)-Cell Therapy: BCMA CAR-T Cells (Autologous), Allogeneic BCMA CAR-T Cells
3) By Bispecific Antibodies: BCMA x CD3 Bispecific Antibodies, BCMA x CD28 Bispecific Antibodies
Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/b-cell-maturation-antigen-bcma-targeted-therapies-global-market-report
Where Is the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth Most Prominent?
North America was the largest region in the B-cell maturation antigen (BCMA) targeted therapies market in 2024. The regions covered in the B-cell maturation antigen (BCMA) targeted therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Is Covered In The B-Cell Maturation Antigen (BCMA) Targeted Therapies Global Market Report?
- Market Size Analysis: Analyze the b-cell maturation antigen (bcma) targeted therapies Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the b-cell maturation antigen (bcma) targeted therapies Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the market.
- Market Contribution: Evaluate contributions of different segments to the overall b-cell maturation antigen (bcma) targeted therapies market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the b-cell maturation antigen (bcma) targeted therapies market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20718
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Key Influencer in the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market 2025: Rising Incidence Of Multiple Myeloma Driver here
News-ID: 3879016 • Views: …
More Releases from The Business Research Company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for BCMA
BCMA-Targeted CAR-T Cell Therapy Market Poised for Robust Growth by 2033
London, UK - September 2025 | Strategic Revenue Insights Inc. The global BCMA-Targeted CAR-T Cell Therapy market is rapidly emerging as a transformative segment within oncology, redefining treatment paradigms for hematologic malignancies, particularly multiple myeloma. Valued for its personalized approach and precision targeting, BCMA-focused CAR-T therapies leverage a patient's immune system to combat cancer cells effectively. The growing incidence of multiple myeloma, coupled with advancements in CAR-T engineering, underscores the…
Targeting Tomorrow: Advancements and Opportunities in the BCMA-Targeted Therapy …
In today's dynamic global economy, the B cell maturation antigen targeted therapy market is emerging as a beacon of opportunity and innovation. With rapid technological advancements, evolving consumer demands, and proactive government policies shaping the landscape, this sector is setting the stage for transformative change. Our in-depth analysis delves into historical market trends, current dynamics, and future projections, providing industry leaders, investors, and decision-makers with the strategic insights needed to…
Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market - Opportunitie …
Dhirtek Business Research and Consulting recently released its most comprehensive research report to date on the global b-cell maturation antigen (bcma) targeted therapies market. Through extensive research, analysts have provided an extensive look into the market's drivers and restraints, and identified the key milestones and trends that will shape its future.
Primary and secondary research methods were used to create this in-depth report. Through the analysis of the research, Dhirtek was…
Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market and Clinical Tri …
Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market and Clinical Trials Insight 2026 Report Analysis and Data Highlights:
* Research Methodology
* Global and Regional Market Analysis
* Global BCMA Targeted Drugs Market Opportunity Assessment: > USD 4 Billion
* Market and Drug Sales Insight 2020 Till 2026
* Approved Drug In Market: 2 Drugs
* Approved BCMA Targeted Drugs Patent, Price and Sales insight 2020 Till 2026
* Future Market Assessment By Indication Till 2026
*…
B-Cell Maturation Antigen (BCMA) Targeted Therapies Market 2022 | Detailed Repor …
The B-Cell Maturation Antigen (BCMA) Targeted Therapies research report undoubtedly meets the strategic and specific needs of the businesses and companies. The report acts as a perfect window that provides an explanation of market classification, market definition, applications, market trends, and engagement. The competitive landscape is studied here in terms of product range, strategies, and prospects of the market’s key players. Furthermore, the report offers insightful market data and information…
B-cell Maturation Antigen (BCMA) Targeted Therapies Market - Insights, Size, Ana …
The Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, by product type (CAR-T cell, bispecific antibodies, and antibody drug conjugates), and by indication (acute lymphoblastic leukemia, and multiple myeloma) has potential products in pipeline, as highlighted in a new report published by Coherent Market Insights. Increasing number of BCMA targeted therapies in pipeline and increasing prevalence of multiple myeloma are expected to favor growth of the B-cell maturation antigen (BCMA)…
